Seoochre

Artificial Intelligence (AI) and machine learning-based technologies have the potential to transform healthcare because they offer new and important insights derived from the vast amount of data generated during the delivery of healthcare every day. The capacity of AI to learn from real-world feedback and improve its performance makes this technology uniquely suited as Software as a Medical Device (SaMD) and is responsible for it being a rapidly expanding area of research and development. Clinical pharmacy practice may undergo major change due to the implementation of this technology. The cha

However, these efforts are haunted by a shortage of resources, restrictions on importing API, social distancing at facilities, disturbed supply chains, and tremendous pressure to quickly manufacture and distribute products. Despite these arduous circumstances, it remains critical for pharma companies to maintain quality and compliance and follow regulatory guidelines. Doing so requires pertinent measures to ensure adherence to Current Good Manufacturing Practice (CGMP) guidelines, and data integrity to meet the requirements of regulators including the U.S. Food and Drug Administration (FDA),

Biologics are basically the products which are developed and produced from living organisms like human, plant or animal cells and, of course, microorganisms (bacteria, yeast, etc.). Having no definite structure, biologics are large and complex molecules which undergo sophisticated procedures while being developed and manufactured. Monoclonal antibodies, hormones, enzymes, insulin, etc. can be referred to as biologics.

Generics are simple molecules and exact copies of approved brand drugs. Contrary to biologics, generics are easier to synthesize, purify and manufacture. Drugs such as phenyt

Cancer drug resistance is complex phenomenon and can be categorised as intrinsic or acquired resistance. In few cases, cancer cells survive even at the clinically relevant doses of established standard chemotherapy which is called as intrinsic resistance whereas at some instances after attaining promising result at initial phases, therapy suddenly turns out to be non-responsive and leads to recurrence of tumour growth. This acquired drug resistance often called as Multi Drug Resistance (MDR) when cancerous cells develop resistance and cross resistance to functionally or even structurally unre

Soft gels, also known as soft capsules or soft caps, are a highly popular pharmaceutical and nutraceutical dosage form, with around 2,500 units consumed every second globally. A forecast by HJR Research predicts a CAGR of 5.5 per cent over the next decade, with the global market value expected to reach $756 billion by 2025. During the same period, the Asia-Pacific region is projected to be the fastest-growing market at a CAGR of 6 per cent, in terms of value. Driven by the increasing popularity of nutraceuticals, where clean label and comfort in swallowing are key factors in customer buying d

Using big data to design clinical trials better and predict outcomes can make it commercially feasible to develop drugs for smaller patient populations. Pharmaceutical companies are looking to big data to reduce costs in research and development and manufacturing. With the explosion of health-related data in recent years, the market for artificial intelligence in drug development, valued at US$200 million in 2015, ballooned to US$700 million in 2018 and is predicted to appreciate more than US$5 billion in 2024, according to a report by big data analytics. Artificial Intelligence (AI) and big

Biopharma’s efforts to digitally transform operations are proving more important than ever to drive improvements in process efficiency and deliver essential treatments to patients. However, the industry’s attempts are returning mixed results and the digital transformations of many enterprises remain in early-phase development. As with any business initiative, a lack of clear goals and strategies keeps some biopharma programs from being successful. As a result, these shortfalls may be further preventing many companies from moving toward the more data-driven future the industry needs to deliver

To bring this into reality, pharmaceutical PV organisations need to move into a “digitalised future” where technology plays a key role in PV processes. This includes automating and streamlining the information streams to reduce complexity, from case processing to reporting. Once automated, companies need to begin to look to artificial intelligence to add further value from their data.

By applying artificial intelligence (AI) and data science approaches, organisations can turn the overabundance of data from being a challenge to solve, into an opportunity. A well-designed, automated, AI-powe

There's a need consolidate natural information with computational strategies for extricating important and fitting qualities from the thousands of qualities measured. Artificial Intelligence (AI) has been connected within the sedate disclosure field for decades. Today, conventional machinelearning modelling has advanced into an assortment of unused strategies, such as combi-QSAR and crossover QSAR, and remains a prevalent approach to consider different drug-related themes. There are different drugs on the showcase and/or in clinical trials that have been outlined by computational strategies.

In this editorial, we explore the remarkable potential of artificial intelligence (AI) and machine learning (ML) in revolutionizing the field of drug design. Traditional drug discovery pipelines have long been plagued by high costs, lengthy timelines, and low success rates. However, with the advent of AI and ML, a new era of accelerated and improved drug design is on the horizon. This editorial highlight the various applications of AI and ML in drug design, including target identification, virtual screening, de novo design, synthesis prediction, and clinical trial optimization. We also addres

Quantum computing is a field that uses quantum mechanics to solve complex problems faster than classical computers. It emerged in the 1980s when it was discovered that certain computational problems could be tackled more efficiently with quantum algorithms than with their classical counterparts. Unlike classical computers that use bits, which can only be 1 or 0, quantum computing involves qubits that can exist in a multidimensional state. The power of quantum computers grows exponentially with more qubits, while classical computers that add more bits can increase power only linearly. Quantum

This article explores the transformative shift toward patient-centric clinical trials, emphasizing active patient involvement in study design, recruitment strategies, and the integration of Patient-Reported Outcomes (PROs). By prioritizing transparency, communication, and digital health technologies, patient-centric trials enhance engagement, streamline recruitment, and improve data quality. The approach holds the potential to accelerate drug development, but challenges like regulatory hurdles and data privacy concerns must be addressed collaboratively for widespread implementation.

This article explores the intricate relationship between Big Pharma and healthcare policies in the United States, unraveling the historical context, lobbying tactics, and policy impact. It delves into specific examples, such as the opioid crisis, and examines reform efforts amid public backlash. The influence on drug approval, pricing, and the role of patient advocacy groups are scrutinized, emphasizing the need for transparency and accountability. The article concludes by highlighting the complex challenges policymakers face in balancing innovation with public health.

Dementia is the first sign of neuronal impairment related to Alzheimer’s disease (AD). The neurodegeneration initially appears in the hippocampus and cortex which comprises memory developing area of the brain and then spreads to additional areas of the brain causing significant shrinkage of the brain. Due to this abnormality accumulation of amyloid β plaques and tau tangles occurs consequently leading to disruption of the functioning of healthy neurons and loss of synaptic connections. Donepezil, memantine, rivastigmine, galantamine, and their combinations are primarily used for the treatment

Certainly, we are all alike, but we are all unique. And the notion that medication would be used in a way that overlooks those disparities is as absurd as walking to a sneaker store to pick up any old pair of sneakers without first verifying the size. Personalized medicine provides an excellent chance to transform a "one size fits all" strategy to diagnostics, pharmacological therapy, and treatment into a personalised strategy. Nanotechnology advancements have enabled the development of nanomaterials devices for the enhanced diagnosis and tailored treatment of a various range of complicated d

The global AI in the pharma market expanded to a size of nearly $699.3 million in 2020. The market is anticipated to increase at a rate of 32.9 %, from $699.3 million in 2020 to $ 2,895.5 million in 2025. Researchers claim that the application of these technologies enhances decision-making, maximizes creativity, increases the effectiveness of research and clinical trials, and produces new tools that benefit doctors, patients and regulators.Computer-aided drug designs have recently supplanted more traditional methods of medication development. A lot of AI is being applied to advance drug desig

Globally, cancer has been referred to as one of the most debilitating diseases. The current treatment regimenfor the treatment of the same is limited to surgical, radiation, and chemotherapeutic interventions. However, these methods have a high risk of damage to healthy tissues, while not even conferring complete cancer eradication. With the advent of nanotechnology, the treatment landscape for cancer is projected to change. While these Nano particulate modalities are highly efficacious, they pose their set of caveats. Recent studies have corroborated the enormous potential of Plant-derived e

The creation of smart nanocarrier-based drug delivery systems, also known as Smart Drug Delivery Systems(SDDSs), was prompted by the nonspecific dispersion and unpredictable release of pharmaceuticals in Conventional Drug Delivery Systems (CDDSs). To lessen the adverse consequences associated with CDDSs, SDDSs can deliver medications to target locations with lower dose frequency and in a spatially controlled way. Chemotherapy is commonly used to treat cancer, the world's second most common cause of death. The SDDSs have sparked a lot of attention as a potential alternative to chemotherapy bec

Nutraceuticals are the supplements that help to prevent disease and maintain the normal body function. Nutraceuticals are gaining popularity due to their nutritional and medicinal effect. The worldwide nutraceutical market is valued US$117 billion, according to estimates. Herbal nutraceuticals support in maintenance of good health and the increase the health life. Nutraceuticals have shown promising outcomes in the treatment of cancer, neurological diseases, cardiovascular diseases, and other ailments. The purpose of this article is to provide knowledge about nutraceuticals and their applicat

In our constantly changing world, healthcare is an essential element of growth. Pursuing safer, more effective healthcare solutions has led to innovative strategies transforming the industry.

Clinical trials and Contract Research Organisations (CROs) play essential roles in these transformative methods. Let's explore these approaches and understand how they contribute to making healthcare safer and more effective.

Technological advancements, evolving patient expectations, and the need for proven, evidence-based therapies collectively drive substantial changes in the healthcare sector. T